Immunovia Sets Exercise Price for TO2 Warrants and Funding Details

Immunovia Secures Funding through TO2 Warrant Program

Immunovia AB (publ) has officially determined the exercise price for its series TO 2 warrants. The price is set at SEK 0.46, creating a solid foundation for the company as it prepares for new initiatives. The exercise period for these warrants will commence shortly, starting on January 2, 2025, and concluding on January 16, 2025. It is crucial for holders to exercise their warrants before the deadline, as unexercised warrants will expire without value.

CEO Comments on Strategic Financial Moves

Jeff Borcherding, the CEO of Immunovia, expressed optimism regarding the recent developments. He stated, "Securing the TO2 warrants on reasonable terms reduces risk and enables us to achieve key milestones. The proceeds will help introduce our next-generation test to the US market in the latter half of 2025 and support clinical studies for reimbursement efforts for the test." This highlights Immunovia's commitment to innovation in diagnostics.

Subscription and Guarantee Commitments

The company reported that it has received substantial subscription commitments, totaling approximately SEK 0.1 million, along with guarantees reaching SEK 36.3 million from external professional investors. This funding is conditional on extraordinary general meeting approvals if necessary. The total secured amount translates to around SEK 37.2 million, equivalent to 65% of the overall warrant program.

Understanding the Warrant Program

The design of the rights issue, completed in late 2024, consisted of two shares and two TO2 warrants as well as one TO3 warrant per unit. If all warrants are exercised, Immunovia could witness a considerable injection of approximately SEK 57.2 million before costs, reinforcing its cash flow for ongoing projects.

Details on Exercise and Trading

Holders aiming to exercise their warrants are advised to notify the company well in advance of the expiration date of January 16, 2025. Trading of the TO2 warrants will be active until January 14, 2025, under the ticker IMMNOV TO 2. The market is currently showing demand for these securities, reflecting investor interest in Immunovia's strategic advancements.

Future Capital Raising Plans

The Board of Directors is considering the next steps concerning capital raising. Given current market conditions, the focus is on solidifying the execution of the warrant program and potentially considering a Directed Share Issue based on shareholder interest and market response after the warrant exercise results are announced.

Potential Impact on Share Capital

If all TO2 warrants are fully exercised, the share capital of Immunovia will rise by a maximum of SEK 3,732,719.34, increasing the total number of outstanding shares significantly. This potential dilution of 42.3% should be closely monitored by existing shareholders.

Company's Mission and Market Reach

Immunovia's mission is to enhance survival rates for pancreatic cancer patients through early detection strategies. With a focus on developing blood tests that identify at-risk individuals, the company principal market is in the USA, where it estimates 1.8 million high-risk individuals could benefit from annual testing.

Contact Information

For further inquiries, shareholders and interested parties can contact:
Jeff Borcherding, CEO
Email: jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl, CFO
Email: karin.almqvist.liwendahl@immunovia.com
Phone: +46 70 911 56 08

Frequently Asked Questions

What is the exercise price for the TO2 warrants?

The exercise price for the TO2 warrants is set at SEK 0.46.

When is the exercise period for the warrants?

The exercise period begins on January 2, 2025, and ends on January 16, 2025.

What commitments has Immunovia received?

Immunovia has received subscription commitments of approximately SEK 0.1 million and guarantee commitments of SEK 36.3 million from investors.

How can warrant holders exercise their warrants?

Warrant holders can exercise their warrants by notifying the issuing agent before the expiration date of January 16, 2025.

What is Immunovia's focus in the diagnostic market?

Immunovia is dedicated to early detection of pancreatic cancer through innovative blood-based testing.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.